Replies to post #824273 on NorthWest Biotherapeutics Inc (NWBO)

[Doc logic]

Slave1,

Eden was supposed to get into the ability for T-cell expansion but the newer model was too big. The Ori connection takes advantage of T-cell advances that would likely be caught up to by others if not moving forward quickly enough. This is a time advantage situation for NWBO as long as there is a compatible partner like Ori willing to value the IP NWBO has with regard to T-cell activation by properly prepared and selected DCs. The new advisor can put everything into proper perspective with a very competent third party view; ). Best wishes.

[Bright Boy]

Thanks a mil for your comments !! Having been invested in NW for over 8 years, it is my understanding that the DCs for DCVax-L for any kind of operable tumor are always the barnacle cells. That is Linda Powers/NW's laser focus for now. The other technologies and IP (other forms of DCs, T cells, CKM, etc. etc. are all for the future). They are part of the treasure chest that Linda Powers and team NW have assembled in order to build the dominant franchise in DC technologies and related technologies. They will make use of various portions of these other technologies when they are ready as they go forward with their business strategy.

Again, thank you for your astute and very knowledgable comments as you outline the present and future strategies for what many professionals believe is and will continue to believe is one of the great strategies of all time and definitely the most sophisticated and effective strategies for treating operable cancers in medical history !!!!

Cheers,

BH